NCT02327039View on ClinicalTrials.gov

The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Type 2 Diabetes
Interventions
DRUG

Dapagliflozin

Sodium glucose cotransporter-2 inhibitor

DRUG

Placebo

Tables of Dapagliflozin placebo

Trial Locations (1)

35128

Division of Metabolic Diseases, University Hospital of Padova, Padua

All Listed Sponsors
collaborator

Azienda Ospedaliera di Padova

OTHER

lead

University of Padova

OTHER

NCT02327039 - The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter